These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7512280)
1. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract. Akaza H; Kotake T; Miyanaga N; Koiso K Semin Oncol; 1994 Feb; 21(1 Suppl 1):70-4. PubMed ID: 7512280 [No Abstract] [Full Text] [Related]
2. Recombinant human granulocyte colony stimulating factors: therapeutic application in the prevention of chemotherapy-induced neutropenia. Gabrilove JL; Jakubowski A; Scher H; Sternberg C; Wong G; Grous J; Yagoda A; Fain K; Moore MA; Clarkson B Behring Inst Mitt; 1988 Aug; (83):229-33. PubMed ID: 2467654 [No Abstract] [Full Text] [Related]
3. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma. Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183 [TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Scher HI J Urol; 1992 Nov; 148(5):1625-6. PubMed ID: 1433578 [No Abstract] [Full Text] [Related]
5. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract. de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278 [No Abstract] [Full Text] [Related]
6. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management]. Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364 [TBL] [Abstract][Full Text] [Related]
7. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373 [TBL] [Abstract][Full Text] [Related]
8. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study. Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950 [TBL] [Abstract][Full Text] [Related]
13. [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy]. Miura T; Murai T; Shimura H; Kondo I Hinyokika Kiyo; 1993 Mar; 39(3):209-12. PubMed ID: 7685138 [TBL] [Abstract][Full Text] [Related]
14. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract. Koch MO; Coussens D Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122 [No Abstract] [Full Text] [Related]
15. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR; Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323 [TBL] [Abstract][Full Text] [Related]
17. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity. Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342 [TBL] [Abstract][Full Text] [Related]